Effects of <font color="blue">low_2</font> <font color="blue">-_2</font> <font color="blue">dose_2</font> <font color="blue">aspirin_3</font> on clinic and ambulatory blood pressure in treated hypertensive patients . Collaborative Group of the Primary Prevention Project ( PPP)--Hypertension study . 
<br>
<br> <font color="blue">Nonsteroidal_2</font> <font color="blue">antiinflammatory_2</font> <font color="blue">drugs_2</font> may affect blood pressure ( BP ) control in hypertensive patients receiving <font color="blue">drug_1</font> <font color="blue">treatment_1</font> <font color="blue">,_1</font> but data on the effects of <font color="blue">low_2</font> <font color="blue">-_2</font> <font color="blue">dose_2</font> <font color="blue">aspirin_3</font> are scanty . This study assessed the effects of <font color="blue">chronic_1</font> <font color="blue">treatment_1</font> with <font color="blue">low_2</font> <font color="blue">doses_2</font> <font color="blue">of_2</font> <font color="blue">aspirin_4</font> ( 100 mg / day ) on clinic and ambulatory systolic ( SBP ) and diastolic ( DBP ) BP in hypertensives on <font color="blue">chronic_1</font> <font color="blue">,_1</font> <font color="blue">stable_1</font> <font color="blue">antihypertensive_2</font> <font color="blue">therapy_2</font> <font color="blue">._2</font> The study was conducted in the framework of the Primary Prevention Project ( PPP ) , a randomized , controlled factorial trial on the preventive effect of <font color="blue">aspirin_2</font> <font color="blue">or_1</font> <font color="blue">vitamin_2</font> <font color="blue">E_2</font> in people with one or more cardiovascular risk factors . Fifteen Italian hypertension units studied 142 hypertensive patients ( 76 men , 66 women ; mean age 59 + /- 5.9 years ) treated with different <font color="blue">antihypertensive_1</font> <font color="blue">drugs_1</font> <font color="blue">:_1</font> 71 patients were randomized to <font color="blue">aspirin_4</font> and 71 served <font color="blue">as_1</font> <font color="blue">controls_3</font> <font color="blue">._3</font> All patients underwent a clinic BP evaluation with an automatic sphygmomanometer and a 24-h ambulatory BP monitoring , at baseline and after 3 months of <font color="blue">aspirin_1</font> <font color="blue">treatment_1</font> <font color="blue">._1</font> At the end of the study the changes in clinic SBP and DBP were not statistically different in treated and untreated subjects . Ambulatory SBP and DBP after 3 months of <font color="blue">aspirin_2</font> <font color="blue">treatment_1</font> were similar to baseline : deltaSBP -0.5 mmHg ( 95% confidence intervals [ CI ] from -1.9 to + 2.9 mm Hg ) and deltaDBP -1.1 mm Hg ( 95% CI from -2.5 to + 0.3 mm Hg ) . The pattern was similar in the control group . No interaction was found between <font color="blue">aspirin_1</font> and the most used <font color="blue">antihypertensive_2</font> <font color="blue">drug_2</font> classes ( <font color="blue">angiotensin_2</font> <font color="blue">converting_2</font> <font color="blue">enzyme_2</font> <font color="blue">inhibitors_2</font> <font color="blue">and_1</font> <font color="blue">calcium_2</font> <font color="blue">antagonists_2</font> <font color="blue">)_2</font> <font color="blue">._1</font> Despite the relatively small sample size our results seem to exclude any significant influence of <font color="blue">low_1</font> <font color="blue">-_1</font> <font color="blue">dose_1</font> <font color="blue">aspirin_1</font> on BP control in hypertensives under treatment .